Navigation Links
Viagra could reduce multiple sclerosis symptoms
Date:5/19/2011

Universitat Autnoma de Barcelona researchers have discovered that Viagra drastically reduces multiple sclerosis symptoms in animal models with the disease. The research, published in Acta Neuropathologica, demonstrates that a practically complete recovery occurs in 50% of the animals after eight days of treatment. Researchers are confident that clinical trials soon will be carried out in patients given that the drug is well tolerated and has been used to treat sexual dysfunction in some multiple sclerosis patients.

Multiple sclerosis is the most common chronic inflammatory disease of the central nervous system and one of the main causes of disability among young adults. The disease is caused by the presence of multiple focuses of demyelination (loss of myelin sheaths around the axons, affecting the ability of neurons to communicate) and neurodegeneration in different areas of the central nervous system. There is currently no cure for the disease, although some drugs have proven effective in fighting symptoms and preventing it from progressing.

A research team from the UAB Institute of Biotechnology and Biomedicine directed by Dr Agustina Garca, in collaboration with the research team directed by Dr Juan Hidalgo from the UAB Institute of Neurosciences, has studied the effects of a treatment using sildenafil, sold as Viagra, in an animal model of multiple sclerosis known as experimental autoimmune encephalomyelitis (EAE). Researchers demonstrated that a daily treatment with sildenafil after disease onset quickly reduced clinical signs, with a practically complete recovery in 50% of the cases after eight days of treatment. Scientists observed how the drug reduced the infiltration of inflammatory cells into the white matter of the spinal cord, thus reducing damage to the nerve cell's axon and facilitating myelin repair.

Sidenafil, together with tadalafil (Cialis) and vardenafil (Levitra), form part of a group of vasodilator drugs known as phosphodiesterase type 5 (PDE5) inhibitors, used in the treatment of erectile dysfunction and pulmonary arterial hypertension. Recent studies in animal models of central nervous system pathologies already pointed to the fact that in addition to vasodilation, these drugs could contain other neuroprotective actions and suggest their usefulness as possible treatments of both acute (cerebrovascular stroke) and chronic (Alzheimer's) neuropathologies. In fact, in a research published in 2010 in the Journal of Neurochemistry, the same research group from UAB demonstrated that one of these inhibitors reduced neuroinflammation and neuronal damage in animal models of traumatic brain injury.


'/>"/>

Contact: Agustina Garcia
Agustina.garcia@uab.cat
34-935-812-802
Universitat Autonoma de Barcelona
Source:Eurekalert  

Related medicine news :

1. Pediatricians Want to Restrict Ads for Tobacco, Booze, Viagra
2. Drugs Like Viagra Linked to Higher Rates of STDs
3. FDA Panel Votes Against Approval of Female Viagra
4. FDA Panel Weighs OK of Female Viagra
5. Viagra Linked to Hearing Loss
6. Viagra May Aid Those With Lung Fibrosis
7. UAB study examines hearing loss, Viagra use
8. Study Explores Possibility of a Female Viagra
9. Implant jab could solve the misery of back pain
10. Simple fitness test could predict long-term risk for heart attack, stroke in middle-aged people
11. Half of prostate cancers could potentially benefit from new type of cancer drugs, U-M study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Viagra could reduce multiple sclerosis symptoms
(Date:6/28/2017)... ... June 28, 2017 , ... ... communities throughout the greater Cincinnati metropolitan area, is teaming up with the local ... families with children receiving treatment in nearby hospitals. , Ronald McDonald House of ...
(Date:6/27/2017)... ... 2017 , ... Harbour , a DAO (decentralized autonomous organization) that harnesses ... released their technical specifications . , 2017 has seen an explosion of token ... determining which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of ...
(Date:6/27/2017)... , ... June 27, 2017 , ... From June 20-22, ... three-day event was held in Syracuse, New York, where EarQ is headquartered. , ... how to connect with today’s savvy consumer, and the latest in hearing technology. ...
(Date:6/27/2017)... New York, NY (PRWEB) , ... June 27, ... ... communications and marketing experts to contribute to an upcoming case studies guidebook. This ... or her organization. , This book will include articles, case studies and how-to’s ...
(Date:6/27/2017)... ... ... Hammer Strength, the world’s leading performance strength training brand, and the National ... the NBSCA Strength & Conditioning Coach of the Year. , In its 11th ... select the coach who embodies the highest level of excellence and outstanding service to ...
Breaking Medicine News(10 mins):
(Date:6/1/2017)... BLUE BELL, Pa. , June 1, 2017 /PRNewswire/ ... Nutriceuticals (PRN) and Veterinarian Recommended Solutions (VRS), and KD ... direct investment in Nutriceutical Holdings by KD Pharma Group. ... Nutriceutical Holdings with the option to acquire the entire ... ideal partner in KD. They are committed to growing ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
(Date:5/26/2017)... , May 25, 2017  In response to the ... , Direct Relief is working with Pfizer to make ... at no cost to community health centers, free and ... nationwide. "Pfizer has a long-standing commitment ... and ensuring patient safety through educational activities," said ...
Breaking Medicine Technology: